Back to Search Start Over

Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients.

Authors :
Sasidharan Nair, Varun
M Toor, Salman
Z Taha, Rowaida
Ahmed, Ayman A
Kurer, Mohamed A
Murshed, Khaled
Soofi, Madiha E
Ouararhni, Khalid
M. Alajez, Nehad
Abu Nada, Mohamed
Elkord, Eyad
Source :
Vaccines; Mar2020, Vol. 8 Issue 1, p71, 1p
Publication Year :
2020

Abstract

T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME). However, the precise role of TIM-3 in colorectal cancer (CRC) TME is yet to be elucidated. We performed phenotypic and molecular characterization of TIM-3<superscript>+</superscript> T cells in the TME and circulation of CRC patients by analyzing tumor tissues (TT, TILs), normal tissues (NT, NILs), and peripheral blood mononuclear cells (PBMC). TIM-3 was upregulated on both CD4<superscript>+</superscript> and CD3<superscript>+</superscript>CD4<superscript>−</superscript> (CD8<superscript>+</superscript>) TILs. CD4<superscript>+</superscript>TIM-3<superscript>+</superscript> TILs expressed higher levels of T regulatory cell (Tregs)-signature genes, including FoxP3 and Helios, compared with their TIM-3<superscript>−</superscript> counterparts. Transcriptomic and ingenuity pathway analyses showed that TIM-3 potentially activates inflammatory and tumor metastatic pathways. Moreover, NF-κB-mediated transcription factors were upregulated in CD4<superscript>+</superscript>TIM-3<superscript>+</superscript> TILs, which could favor proliferation/invasion and induce inflammatory and T-cell exhaustion pathways. In addition, we found that CD4<superscript>+</superscript>TIM-3<superscript>+</superscript> TILs potentially support tumor invasion and metastasis, compared with conventional CD4<superscript>+</superscript>CD25<superscript>+</superscript> Tregs in the CRC TME. However, functional studies are warranted to support these findings. In conclusion, this study discloses some of the functional pathways of TIM-3<superscript>+</superscript> TILs, which could improve their targeting in more specific therapeutic approaches in CRC patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2076393X
Volume :
8
Issue :
1
Database :
Complementary Index
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
142496635
Full Text :
https://doi.org/10.3390/vaccines8010071